EXPIRED
April 5, 2023
PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
National Cancer Institute (NCI)
The purpose of this Notice is to encourage currently funded NCI extramural investigators to apply for administrative supplements to study cancer control and prevention in low- and middle-income country (LMIC) settings using economic or costing data and methods.
Background
The global health and economic burden of cancer is increasingly concentrated in LMICs, where economic factors at the individual, community and policy levels have substantial relevance for and impact on cancer outcomes. Costs can pose a substantial barrier to access to treatment, for example, which is likely to have a disproportionate impact in LMICs. Cancer diagnosis and treatment impose a high financial burden on patients and their families, including direct medical and non-medical costs, as well as indirect costs, such as lost income. Indeed, cancer is associated with the highest economic loss among leading causes of death worldwide. Development of the human, technical, and infrastructure resources needed to provide cancer care have the potential to place an enormous strain on already overstrained health systems. Moreover, implementation barriers for effective cancer control interventions in LMICs are often related to cost and economic conditions. Thus, global health experts have identified affordability of cancer care, value-based care, and health economics as key priority areas for cancer research in LMICs.
Evaluations of the economic costs of cancer and cancer control vary across countries and settings based on the disease burden, the availability of healthcare resources, access to care utilization and outcomes data, ability to measure financial burden or toxicity, and healthcare practices. There is a lack of data and rigorous research to address economic aspects of cancer and cancer control in LMICs. Little is known about the economic impact of a cancer diagnosis for patients and their families in LMICs. A 2016 bibliometric analysis estimated that at that time only 8% of published economic evaluations of health interventions addressed low- or lower-middle income countries. Additionally, most evidence regarding cost effectiveness of cancer screening and treatment comes from high- or upper-middle-income countries, and existing methods for health economic analyses are largely based on high-income populations and may not adequately account for different health and economic contexts. Economic modeling can also be used to guide policy decisions and inform selections between different cancer control strategies. But the lack of economic data from LMICs is a challenge for countries in the process of prioritizing interventions and programs for cancer control. An analysis of 158 national cancer control plans conducted in 2018 showed that only 16 plans provided details about costing and budgeting. More studies are needed in low- and lower-middle-income countries to generate data to inform and build the economic case for cancer control and prevention in LMICs.
Research Objectives
This supplement opportunity encourages research that uses economic or costing data and methods to study cancer control in LMICs. Research may involve the use of economic data to assess medical costs associated with cancer control or care, to understand non-medical costs, or to study the application of economic data to inform policy decisions. Studies may utilize a range of possible approaches including original data collection, secondary data analysis, modeling using available data, or methods development. The parent award need not have included an economic outcome or measures. However, the supplemental funding request must propose to enhance the parent award through incorporating economic or costing analyses or methods to extend the existing research aims. Applicants are encouraged to leverage existing resources and partnerships, and to design projects that can reasonably be completed within the given time and budget.
Specific areas of interest include, but are not limited to the following:
Individual level
Community level
Health System and Policy level
Requirements
Applications responsive to this NOSI must:
Applications not responsive to this NOSI include:
Eligibility
Administrative supplements may only be used to meet increased costs that are within the scope of the approved award but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted.
Applications for this initiative must be submitted using the following opportunity or its subsequent reissued equivalent.
All instructions in the SF424 (R&R) Application Guide and PA-20-272 must be followed, with the following additions:
Budget and Period of Support
Page limits
These sections have the following page limits:
Administrative Review Process
NCI will conduct administrative reviews of submitted applications and will support the most meritorious applications submitted for consideration, based upon availability of funds.
Criteria:
Applicants are strongly encouraged to notify the program contact at the Institute supporting the parent award that a request has been submitted in response to this NOSI to facilitate efficient processing of the application.
Applicants are encouraged to discuss their application with the scientific/research contact listed in this NOSI prior to submission.
Please direct all inquiries to:
Mark Parascandola, PhD, MPH
Center for Global Health
National Cancer Institute (NCI)
Telephone: 240-276-6871
Email: paramark@mail.nih.gov
Financial/Grants Management Contact
Dawn Mitchum
National Cancer Institute (NCI)
Telephone: 240-276-5699
Email: dawn.mitchum@nih.gov